Journal article
HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific
Biomedicine & pharmacotherapy, v 57(1), pp 41-48
2003
PMID: 12642036
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) is a 14 kDa virion-associated protein that transactivates the HIV-1 long terminal repeat (LTR) as well as other eukaryotic promoters. Vpr also functions in nuclear localization and import of the HIV-1 preintegration complex (PIC), cell cycle arrest at the G
2/M interface, and virion packaging. Electrophoretic mobility shift analysis has been utilized to demonstrate a direct association between purified Vpr (strain pNL4-3) and HIV-1 LTR sequences that span the adjacent C/EBP site I, NF-κB site II, and ATF/CREB binding site (nt –95 to –130, relative to the start of transcription). A similar interaction has been observed between HIV-1 Vpr and LTR C/EBP site II (nt –167 to –175). A total of 94.7% of LTRs derived from peripheral blood contained C/EBP site I variants that displayed a high relative Vpr binding affinity phenotype, while only 5.3% exhibited a low relative Vpr binding affinity phenotype. All LTRs derived from peripheral blood exhibited a high relative Vpr binding phenotype at C/EBP site II. These results suggest a preference for the maintenance of two
cis-acting elements with high affinity for Vpr within LTRs derived from peripheral blood. Additional studies have also demonstrated that naturally occurring sequence variation within C/EBP site I and II can dramatically alter the relative affinity of Vpr for these
cis-acting elements. These studies suggest that Vpr may regulate the interaction of members of the C/EBP transcription factor family with the viral LTR.
Metrics
Details
- Title
- HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific
- Creators
- Tricia H Hogan - Department of Microbiology and Immunology, The Pennsylvania State University, College of Medicine, (H107), 500 University Drive, P.O. Box 850, Hershey, PA 17033, USAMichael R Nonnemacher - Department of Microbiology and Immunology, The Pennsylvania State University, College of Medicine, (H107), 500 University Drive, P.O. Box 850, Hershey, PA 17033, USAFred C Krebs - Department of Microbiology and Immunology, The Pennsylvania State University, College of Medicine, (H107), 500 University Drive, P.O. Box 850, Hershey, PA 17033, USAAndrew Henderson - Department of Veterinary Science, The Pennsylvania State University, University Park, Pennsylvania 16802, USABrian Wigdahl - Department of Microbiology and Immunology, The Pennsylvania State University, College of Medicine, (H107), 500 University Drive, P.O. Box 850, Hershey, PA 17033, USA
- Publication Details
- Biomedicine & pharmacotherapy, v 57(1), pp 41-48
- Publisher
- Elsevier SAS
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000182033400007
- Scopus ID
- 2-s2.0-0037225814
- Other Identifier
- 991014877696904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Medicine, Research & Experimental
- Pharmacology & Pharmacy